GlassScriptPhysician profile
Alan J Mushnick
NPI 1942297866
$16,667.85
in general payments reported to CMS, 2019-2025
37 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,792 · 2020: $676 · 2021: $1,553 · 2022: $2,161 · 2023: $1,738 · 2024: $2,752 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,486.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,470.54 | 2019 | |
| Abbvie INC. | $2,344.59 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,142.75 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,589.63 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $931.39 | 2019-2025 | Stelara, Tremfya, Simponi |
| Qol Medical, LLC | $791.48 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $482.52 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $404.18 | 2019-2024 | Linzess |
| Celgene Corporation | $398.49 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $392.42 | 2019-2025 | Livdelzi |
| Pfizer INC. | $342.15 | 2019-2025 | |
| Genzyme Corporation | $266.86 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $249.12 | 2019-2022 | |
| Evoke Pharma, INC. | $244.72 | 2021-2024 | Gimoti |
| Ardelyx, INC. | $244.21 | 2023-2025 | Ibsrela |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Mushnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.